Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: Case report and review of the literature

被引:13
作者
DeEugenio, DL
Ruggiero, NJ
Thomson, LJ
Menajovsky, LB
Herman, JH
机构
[1] Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA
[2] Thomas Jefferson Univ, Jefferson Antithrombot Therapy Serv, Jefferson Internal Med Associates, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 04期
关键词
heparin; heparin-induced thrombocytopenia; HIT; anticoagulation; thrombosis;
D O I
10.1592/phco.25.4.615.61036
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Early- or abrupt-onset immune-mediated heparin-induced thrombocytopenia (HIT) is defined as HIT that occurs less than 5 days after exposure to heparin in patients who have received heparin within the previous 100 days. We identified no reports in the literature of early-onset HIT in patients who had a heparin-free interval longer than 100 days. However, we report a case of early-onset immune-mediated HIT illustrated by a positive HIT result with serotonin release and enzyme-linked immunosorbent assays, and a decrease in platelet count to less than 100 x 10(3)/mm(3) with no evidence of thrombosis, approximately 165 days after the patient's last exposure to heparin. We conclude that clinicians should choose alternative forms of anticoagulation in patients with even a remote history of HIT. If clinicians are compelled to reexpose patients to heparin, they should confirm a negative HIT assay result, monitor for clinical signs of HIT, and provide appropriate treatment if HIT is suspected.
引用
收藏
页码:615 / 619
页数:5
相关论文
共 13 条
[1]  
GREINACHER A, 2001, HEPARIN INDUCED THRO, P291
[2]   Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety [J].
Hirsh, J ;
Warkentin, TE ;
Shaughnessy, SG ;
Anand, SS ;
Halperin, JL ;
Raschke, R ;
Granger, C ;
Ohman, EM ;
Dalen, JE .
CHEST, 2001, 119 (01) :64S-94S
[3]   Heparin-induced thrombocytopenia - Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin [J].
Lubenow, N ;
Kempf, R ;
Eichner, A ;
Eichler, P ;
Carlsson, LE ;
Greinacher, A .
CHEST, 2002, 122 (01) :37-42
[4]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[5]   Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia [J].
Smythe, MA ;
Warkentin, TE ;
Stephens, JL ;
Zakalik, D ;
Mattson, JC .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (01) :50-52
[6]  
Warkentin T.E., 2001, Heparin-Induced Thrombocytopenia, V2nd ed., P43
[7]   Temporal aspects of heparin-induced thrombocytopenia [J].
Warkentin, TE ;
Kelton, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (17) :1286-1292
[8]  
Warkentin TE, 1999, AM J HEMATOL, V62, P44, DOI 10.1002/(SICI)1096-8652(199909)62:1<44::AID-AJH7>3.0.CO
[9]  
2-F
[10]   Heparin-induced thrombocytopenia and cardiac surgery [J].
Warkentin, TE ;
Greinacher, A .
ANNALS OF THORACIC SURGERY, 2003, 76 (02) :638-648